“Capital injection: China backs AI drug makers in self-reliance drive” — what this page in the network covers. China’s state-backed investors are stepping up funding for artificial intelligence-driven drug developers as Beijing pushes for technological self-reliance, with at least one company already advancing an AI-designed therapy into late-stage clinical trials. Hangzhou-based METiS TechBio, founded in 20 Nova Global News curates publicly available headlines and summaries with source attribution.
Third-party article rights, trademarks, images, and publisher names belong to their respective owners; read the original article at the source for full context. Part of the Nova Ecosystem — the platform where AI apps, news, and tools are built and deployed. For the complete material, the listing points back to the source inside the network.